Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancies

This study is divided into two phases: dose escalation and cohort expansion. The dose escalation stage aims to evaluate the tolerability, pharmacokinetic characteristics and safety of TQB2858 injection in subjects with advanced malignant tumors. The cohort expansion phase aims to evaluate the initial efficacy and safety of TQB2858 injection in patients with soft tissue sarcoma, and to explore treatment-related biomarkers.

Study Overview

• Status: Terminated
• Conditions: Advanced Cancer; Advanced Soft-tissue Sarcoma
• Intervention / Treatment: Drug: TQB2858 injection

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100142
      • Beijing Cancer Hospital
    • Beijing, Beijing, China, 100044
      • Peking University People's Hospital
    • Beijing, Beijing, China, 100144
      • Peking University Shougang Hospital
    • Beijing, Beijing, China, 100000
      • Beijing Jishuitan Hospital
  • Sichuan
    • Chengdu, Sichuan, China, 610000
      • West China Hospital,Sichuan University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Phase I (dose-escalation phase).

  a) Patients with advanced malignant solid/hematologic tumors who have a histologically and/or cytologically confirmed diagnosis and who have failed standard therapy or lack effective therapies.

• Phase II (cohort expansion phase).

  1. Unresectable, recurrent or metastatic adenoid soft tissue sarcoma diagnosed by histology.
  2. Previously received anti-vascular targeted drug therapy
  3. Have at least one measurable lesion Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
• Age: 18 to 70 years old;
• The Eastern Cooperative Oncology Group (ECOG) score: 0 to 1;
• The expected survival period is ≥3 months;
• Normal function of major organs
• Women of childbearing age should agree to use effective contraceptive measures during the study period and 6 months after the end of the study, and have a negative serum or urine pregnancy test within 7 days before enrollment in the study; men should agree to use effective contraception during the study period and after the end of the study period 6 Effective contraceptive measures must be used within one month.
• Patients voluntarily enroll in this study, sign an informed consent form and comply well.

Exclusion Criteria:

• Combined diseases and medical history:

  1. Have presented with or currently have concurrent other malignancies within 2 years.
  2. Unresolved toxic reactions due to any prior treatment above Common Terminology Criteria for Adverse Events(CTCAE) grade 1, excluding alopecia, peripheral sensory nerve disorders.
  3. Major surgical treatment or significant traumatic injury within 28 days prior to the start of study treatment.
  4. Long-term untreated wounds or fractures.
  5. An arterial/venous thrombotic event within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism.
  6. Persons with a history of psychotropic substance abuse who are unable to abstain or have a mental disorder.
  7. Subjects with any severe and/or uncontrollable disease, including:

• Tumor-related symptoms and treatment:

  1. Have received surgery, chemotherapy, radiotherapy or other anti-cancer therapy within 4 weeks prior to the start of study treatment.
  2. Treatment with proprietary Chinese medicines with clear antitumor indications in the National Medical Products Administration (NMPA)-approved drug formulary within 2 weeks prior to the start of study treatment.
  3. Prior receipt of immune dual anti-treatment drugs against the same target of TQB2858 injection.
  4. Uncontrolled pleural effusions, pericardial effusions, or ascites that still require repeated drainage (in the judgment of the investigator);
  5. Brain metastases with less than 4 weeks of stable symptom control after discontinuation of dehydrating agents and steroids.

• Research and treatment related:

  1. History of live attenuated vaccination within 28 days prior to the start of study treatment.
  2. Prior history of severe allergy to macromolecular drugs or allergy to known components of TQB2858 injection.
  3. Active autoimmune disease requiring systemic therapy that occurred within 2 years prior to the start of study treatment.
  4. Diagnosis of immunodeficiency or being treated with systemic glucocorticoids or any other form of immunosuppressive therapy.
• Participation in other clinical trials of antineoplastic drugs within 4 weeks prior to enrollment.
• Subjects who, in the judgment of the investigator, have a concomitant illness that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or for whom other reasons are deemed to exist for ineligibility for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TQB2858 injection; Participants will receive 3 mg/60 mg/600 mg/1200 mg/1800 mg single dose of TQB2858 injection on Day 1, iv (injection of vein), once every three weeks.	Drug: TQB2858 injection; TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD)	If dose limiting toxicity (DLT) occurs in 2 or more subjects in a given dose group, the dose level in the previous dose group is considered MTD.	Baseline up to 48 weeks
Overall response rate (ORR)	ORR refers to the percentage of complete response (CR) or partial response (PR) subjects determined by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or iRECIST (CR and PR under iRECIST criteria can occur after imaging disease progression).	up to 48 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	PFS will be defined as median number of months from the date of randomization until the first documented sign of disease progression or death due to any causes, whichever occurs first.	up to 48 weeks
Duration of Response (DOR)	DOR will be defined as median number of months from date of first documented objective response until first documented sign of disease progression or death due to any causes.	up to 48 weeks
Disease control rate（DCR）	DCR refers to the percentage of subjects with CR, PR, or stable disease (SD) of 6 weeks or more as determined by RECIST 1.1 or iRECIST (CR, PR, SD under iRECIST criteria can occur after imaging disease progression).	up to 48 weeks
Overall survival (OS)	OS is defined as the time from enrollment to death from any cause.	Baseline up to die

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 14, 2022
• Primary Completion (Actual): March 31, 2023
• Study Completion (Actual): June 30, 2023

Study Registration Dates

• First Submitted: December 9, 2021
• First Submitted That Met QC Criteria: December 9, 2021
• First Posted (Actual): December 13, 2021

Study Record Updates

• Last Update Posted (Actual): January 18, 2024
• Last Update Submitted That Met QC Criteria: January 17, 2024
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma
• Other Study ID Numbers: TQB2858-I-05

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No